Keryx Biopharmaceuticals (KERX) Announces Positive Interim Results From Phase 2 Clinical Study For KRX-101 (Sulodexide Gelcaps) For Treatment Of Diabetic Nephropathy. Around 40% of diabetic patients progress to diabetic nephropathy. So far the progression can be delayed by tight blood sugar control etc. However there is no known cure. In the Phase II study, 24 percent of [...]
Keryx Biopharmaceuticals (KERX) Announces Positive Interim Results From Phase 2 Clinical Study For KRX-101 (Sulodexide Gelcaps) For Treatment Of Diabetic Nephropathy.
Around 40% of diabetic patients progress to diabetic nephropathy. So far the progression can be delayed by tight blood sugar control etc. However there is no known cure. In the Phase II study, 24 percent of [...]
Please fill in the following fields
* - Required
Your Name: *
Your E-Mail: *
Your Remarks:
Friend's Name: *
Friend's E-Mail: *
